Thaum Lub Ob Hlis 9, 2026, lub vev xaib official ntawm Center for Drug Evaluation (CDE) ntawm National Medical Products Administration (NMPA) tshaj tawm tias ZL-1310 rau kev txhaj tshuaj, ib qho tshiab DLL3-targeting antibody-drug conjugate (ADC), tau npaj yuav tau txais Breakthrough Therapy Designation.
Ua ib tug tswv cuab ntawm Peking University Cancer Hospital Medical Consortium thiab ib lub tsev kho mob tshwj xeeb hauv Beijing theem ob, Beijing South Region Oncology Hospital International Department siv lub platform kuaj mob thiab kho mob ntau yam kom sai sai los koom ua ke cov kev kho mob thoob ntiaj teb rau hauv cov phiaj xwm kho mob ntawm cov neeg mob thoob ntiaj teb. Yog tias koj lossis ib tus neeg koj hlub tab tom ntsib teeb meem ntawm kev kho mob thib ob lossis tom qab rau mob qog noj ntshav me me, thov nyeem cov ntaub ntawv hauv qab no kom zoo thiab tiv tauj peb tam sim ntawd.
Hu rau Beijing South Region Oncology Hospital International Department tam sim no:
- Xov tooj: 400-880-3716
- Tus lej WeChat: 17801183037
- Email ①: 100085_010@163.com
- Email ②: myimmnet@163.com
**Cov Ntaub Ntawv Tseem Ceeb: Txog li 86% Kev Ua Haujlwm Zoo rau Cov Neeg Mob uas Muaj Kev Nthuav Tawm Hauv Lub Hlwb**
Xyoo 2025, lub rooj sib tham txhua xyoo ntawm American Society of Clinical Oncology (ASCO), cov ntaub ntawv tshawb fawb thoob ntiaj teb theem 1a/1b rau ZL-1310 tau nthuav tawm.
Rau cov neeg mob uas tau kho mob lawm (kev kho mob thib ob):
- Tus nqi teb tsis tau lees paub (uORR) tau txog 67%, nrog rau tus nqi tswj kab mob (DCR) ntawm 97%.
- Hauv pawg tshuaj kho mob zoo tshaj plaws (1.6 mg/kg): Tus nqi teb rau lub hom phiaj (ORR) nce mus txog 79%, nrog rau tus nqi tswj kab mob (DCR) ntawm 100%.
- Qhov no txhais tau tias: Yuav luag txhua 10 tus neeg mob uas tau txais cov tshuaj no tau tswj tau qhov mob qog, thiab yuav luag 8 tus neeg mob tau pom tias qhov mob qog me me heev.
Rau cov neeg mob uas muaj mob qog nqaij hlav metastases hauv lub hlwb uas nyuaj tshaj plaws:
- Cov neeg mob uas muaj mob qog nqaij hlav kis mus rau lwm lub hlwb thaum pib: Qhov feem pua ntawm kev teb rau qhov teeb meem (ORR) yog 68%.
- Cov neeg mob uas tsis tau txais kev kho mob radiotherapy hauv lub taub hau dua li: Qhov kev teb sai sai (ORR) yog siab txog 86%!
Cov ntaub ntawv no yog qhov tseem ceeb heev. Cov tshuaj kho mob ib txwm muaj teeb meem nkag mus rau hauv cov ntshav-lub hlwb thaiv, tab sis ZL-1310 qhia tau tias muaj zog tiv thaiv qog noj ntshav hauv lub hlwb. Rau cov neeg mob thoob ntiaj teb uas txhawj xeeb txog cov kev mob tshwm sim ntawm kev kho mob tag nrho lub hlwb, qhov no sawv cev rau kev cia siab tseem ceeb ntawm "kev zam kev kho mob hluav taws xob hauv lub hlwb."
**Cov Ntaub Ntawv Kev Nyab Xeeb:** Hauv pawg tshuaj tsawg dua 2.0 mg/kg, qhov tshwm sim ntawm cov teeb meem tsis zoo ntsig txog kev kho mob (TRAEs) ntawm qib 3 lossis siab dua tsuas yog 6% xwb, tsis muaj cov xwm txheej mob ntsws interstitial (ILD) lossis kev tso tseg kev kho mob tau tshaj tawm.
—
**III. Vim li cas ho xaiv Beijing South Region Oncology Hospital International Department?**
Rau cov neeg mob thoob ntiaj teb, kev nkag mus rau cov kev kho mob tshiab tsis yog hais txog "seb cov tshuaj puas muaj," tab sis kuj yog ib qho txheej txheem uas muaj kev sib txuas lus uas cuam tshuam txog "leej twg siv tau, yuav siv li cas, thiab leej twg tswj cov kev mob tshwm sim."
Lub Tsev Kho Mob Thoob Ntiaj Teb ntawm Beijing South Region Oncology muab kev ntsuam xyuas yav tom ntej thiab kev tswj hwm tag nrho rau cov kev kho mob tshiab xws li ZL-1310 rau cov neeg mob tsim nyog. Txawm koj yog los ntawm Southeast Asia, Middle East, Tebchaws Europe, lossis Asmeskas, peb muaj cov txheej txheem kev pabcuam kho mob thoob ntiaj teb uas tau tsim tsa zoo.
Peb muab cov kev pabcuam dav dav xws li kev sab laj ua ntej mus pw hauv tsev kho mob, kev txhais lus ntau hom lus, cov ntawv thov vixaj kho mob, mus rau kev saib xyuas kev kho mob. Kev ua raws li txoj cai "ib tus kws kho mob, ib tus neeg mob, ib chav" ua kom koj txoj kev ceev ntiag tug thiab kev hwm raug hwm tag nrho, txawm tias nyob hauv txawv teb chaws.
Tam sim no, ZL-1310 tau txais kev tso cai rau Orphan Drug Designation thiab Fast Track Designation los ntawm US FDA. Nws txoj kev npaj yuav suav nrog hauv Suav teb Breakthrough Therapy Designation yuav ua rau nws nkag mus tau sai dua hauv Suav teb.
Tsis txhob cia cov teeb meem lus, cov ntaub ntawv tsis txaus, lossis cov txheej txheem nyuaj ua rau koj tsis tau txais kev kho mob siab heev. Beijing South Region Oncology Hospital International Department tau tsim ib txoj kev ntsuab rau cov neeg mob thoob ntiaj teb.
Hu xov tooj los yog tiv tauj peb ntawm WeChat los yog email kom qhia koj qhov teeb meem. Peb cov kws pab tswv yim kho mob yuav muab kev ntsuam xyuas ua ntej hauv 24 teev.
- Xov tooj (kev sab laj 24 teev): 400-880-3716
- WeChat (kev sib txuas lus tam sim ntawd): 17801183037 (txhawb nqa lus Askiv thiab Suav)
- Email (rau cov ntaub ntawv kho mob):
- 100085_010@163.com
- myimmnet@163.com
Lub sijhawm tshaj tawm: Lub Ob Hlis-12-2026